Skye Bioscience Gestion

Gestion contrôle des critères 1/4

Le PDG Skye Bioscience est Punit Dhillon, nommé en Aug2020, a un mandat de 4.25 ans. La rémunération annuelle totale est $ 1.81M, composée du salaire de 24.9% et des bonus 75.1%, y compris les actions et options de la société. détient directement 1.12% des actions de la société, d'une valeur de $ 1.44M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 0.7 ans.

Informations clés

Punit Dhillon

Directeur général

US$1.8m

Rémunération totale

Pourcentage du salaire du PDG	24.9%
Durée du mandat du directeur général	4.3yrs
Propriété du PDG	1.1%
Durée moyenne d'occupation des postes de direction	2.5yrs
Durée moyenne du mandat des membres du conseil d'administration	less than a year

Mises à jour récentes de la gestion

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Analyse de la rémunération des PDG

Comment la rémunération de Punit Dhillon a-t-elle évolué par rapport aux bénéfices de Skye Bioscience?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$2m	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$668k	US$433k	-US$19m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$900k	US$400k	-US$9m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$615k	US$160k	-US$7m
Sep 30 2020	n/a	n/a	-US$207k
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$13m
Dec 31 2019	US$65k	n/a	US$1m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$82k	n/a	-US$19m

Rémunération vs marché: La rémunération totale de Punit ($USD 1.81M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 642.87K ).

Rémunération et revenus: La rémunération de Punit a augmenté alors que l'entreprise n'est pas rentable.

PDG

Punit Dhillon (44 yo)

4.3yrs

Titularisation

US$1,807,338

Compensation

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Punit Dhillon	President	4.3yrs	US$1.81m	1.12% $ 1.4m
Kaitlyn Arsenault	Chief Financial Officer	3.1yrs	US$1.27m	0.55% $ 708.6k
Christopher Twitty	Chief Scientific Officer	1.9yrs	pas de données	pas de données
Tu Diep	Chief Development Officer	no data	pas de données	0.27% $ 350.4k
Puneet Arora	Chief Medical Officer	less than a year	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

43.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de SKYE est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Punit Dhillon	President	6.8yrs	US$1.81m	1.12% $ 1.4m
Paul Grayson	Independent Chairman of the Board	1.3yrs	US$1.25m	0.86% $ 1.1m
Andrew Schwab	Director	1.3yrs	US$74.08k	0% $ 0
Louis Aronne	Member of Clinical & Scientific Advisory Board	less than a year	pas de données	pas de données
Annalisa Lisa Jenkins	Independent Director	less than a year	pas de données	0% $ 0
Karen Smith	Director	less than a year	pas de données	0% $ 0
Deborah Charych	Independent Director	1.8yrs	US$102.28k	0% $ 0
Rekha Kumar	Member of Clinical & Scientific Advisory Board	less than a year	pas de données	pas de données
Lee Kaplan	Member of Clinical & Scientific Advisory Board	less than a year	pas de données	pas de données
Beverly Tchang	Member of Clinical & Scientific Advisory Board	less than a year	pas de données	pas de données
Marcus Goncalves	Member of Clinical & Scientific Advisory Board	less than a year	pas de données	pas de données

0.7yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la SKYE n'est pas considéré comme expérimenté ( 0.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Skye Bioscience Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

High number of new directors

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen